CB2 Insights Announces FY2018 Financial Results After Transformative Year

April 30, 2019

CB2 Insights announced its FY2018 financial results after a transformative year. A Merida portfolio company, CB2 focuses on predictive data analytics to bring real-world evidence driven from the point-of-care to the medical cannabis community. 

 

Highlights included total revenue of C$10.8 million up from $280 thousand the year prior, gross profit of C$7.9 million and adjusted EBITDA loss of $1.1 million. CB2 just listed publicly and is a stock worth watching as they are a core articulation of Merida's thesis that medical data will be a crucial element helping medical cannabis shift into cannabis-based medicine.

 

Click here for the full release.

 

 

 

 

 

 

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Investing in Cannabis: Mitch Baruchowitz

May 21, 2019

1/10
Please reload

Recent Posts
Please reload

Archive